Clincosm LogoSign in Get a demo

multiple myeloma in relapse

Showing 26 - 50 of 62
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Apr 13, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Mar 23, 2022

Multiple Myeloma in Relapse Trial in Finland, Sweden (Carfilzomib for Inj 60 milligram (MG), Elotuzumab 400 MG, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib for Inj 60 milligram (MG)
  • +2 more
  • Helsinki, Finland
  • +7 more
Mar 14, 2022

Multiple Myeloma in Relapse Trial in Canada (Daratumumab)

Completed
  • Multiple Myeloma in Relapse
  • Kingston, Ontario, Canada
  • +5 more
Feb 14, 2022

Multiple Myeloma in Relapse Trial in United States (pomalidomide, ixazomib, dexamethasone)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Anchorage, Alaska
  • +335 more
Jan 10, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Boston (TriPRIL CAR T Cells,

Recruiting
  • Multiple Myeloma
  • +2 more
  • TriPRIL CAR T Cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Oct 28, 2021

Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +3 more
  • Boston, Massachusetts
  • +2 more
Oct 28, 2021

Multiple Myeloma in Relapse Trial in Denver, Saint Louis, Toronto (Elotuzumab, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Denver, Colorado
  • +2 more
Oct 14, 2021

Multiple Myeloma in Relapse Trial in Boston, Durham (Panobinostat, Dexamethasone, Lenalidomide)

Completed
  • Multiple Myeloma in Relapse
  • Boston, Massachusetts
  • +3 more
Sep 3, 2021

Multiple Myeloma in Relapse Trial in Worldwide (MP0250 plus BOR+DEX)

Completed
  • Multiple Myeloma in Relapse
  • MP0250 plus BOR+DEX
  • Wien, Vienna, Austria
  • +23 more
Aug 19, 2021

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Wuhan (C-4-29 Cells)

Enrolling by invitation
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • C-4-29 Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 2, 2021

Multiple Myeloma, Tumor, Plasma Cell, Multiple Myeloma in Relapse Trial in Kunming (BCMA targeted prime CAR-T cells)

Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA targeted prime CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
Jul 30, 2021

Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma Trial in Boston (TEG002)

Recruiting
  • Multiple Myeloma, Refractory
  • +2 more
  • TEG002
  • Boston, Massachusetts
  • +2 more
Jul 9, 2021

Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma Trial in Shenzhen, Chengdu (BCMA-CD19 cCAR T

Recruiting
  • Multiple Myeloma in Relapse
  • +2 more
  • BCMA-CD19 cCAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
May 17, 2021

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Tel Aviv (cyclosporine in combination with carfilzomib and

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • cyclosporine in combination with carfilzomib and dexamethasone
  • Tel Aviv, Israel
    Tel Aviv Sourasky Medical Center
Apr 19, 2021

Multiple Myeloma, Tumor, Plasma Cell, Multiple Myeloma in Relapse Trial in Kunming (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
Mar 1, 2021

Multiple Myeloma, Multiple Myeloma in Relapse, Tumor, Plasma Cell Trial in Chongqing (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA CAR-T cells
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 1, 2021

Multiple Myeloma in Relapse Trial in France (Melphalan, Autologous Hematopoietic Stem cell)

Terminated
  • Multiple Myeloma in Relapse
  • Bordeaux, France
  • +7 more
Jan 18, 2021

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse Trial in Hangzhou (CD19/BCMA

Recruiting
  • Multiple Myeloma in Relapse
  • +5 more
  • CD19/BCMA Targeted CAR T-cells and dasatinib
  • CD19/BCMA Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Oct 27, 2020

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in United States (ACTR087, SEA-BCMA)

Terminated
  • Multiple Myeloma
  • +2 more
  • ACTR087
  • SEA-BCMA
  • Phoenix, Arizona
  • +6 more
Mar 27, 2020

Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab Trial in Seoul (Drug Combinations)

Unknown status
  • Multiple Myeloma in Relapse
  • +2 more
  • Drug Combinations
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Aug 21, 2019

Multiple Myeloma in Relapse Trial in Changchun (Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen)

Unknown status
  • Multiple Myeloma in Relapse
  • Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Aug 17, 2019

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in New York (Pomalidomide, Cyclophosphamide, Dexamethasone)

Completed
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Jun 14, 2019

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression Trial in Xi'an (CAR-T Re-treatment)

Unknown status
  • Multiple Myeloma
  • +2 more
  • CAR-T Re-treatment
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Dec 13, 2018

Multiple Myeloma in Relapse Trial in Shenzhen (Treatment)

Unknown status
  • Multiple Myeloma in Relapse
  • Treatment
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital,The first affiliated hospital
Dec 7, 2018